TRAP
MCID: TRD008
MIFTS: 35

Triiodothyronine Receptor Auxiliary Protein (TRAP)

Aliases & Classifications for Triiodothyronine Receptor Auxiliary Protein

MalaCards integrated aliases for Triiodothyronine Receptor Auxiliary Protein:

Name: Triiodothyronine Receptor Auxiliary Protein 57
Trap 57

External Ids:

OMIM 57 190445

Summaries for Triiodothyronine Receptor Auxiliary Protein

MalaCards based summary : Triiodothyronine Receptor Auxiliary Protein, also known as trap, is related to periodic fever, familial, autosomal dominant and thyroid dyshormonogenesis 1. An important gene associated with Triiodothyronine Receptor Auxiliary Protein is TRAP (Triiodothyronine Receptor Auxiliary Protein). The drugs Certoparin and Linagliptin have been mentioned in the context of this disorder. Affiliated tissues include bone, neutrophil and eye.

More information from OMIM: 190445

Related Diseases for Triiodothyronine Receptor Auxiliary Protein

Diseases related to Triiodothyronine Receptor Auxiliary Protein via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1200)
# Related Disease Score Top Affiliating Genes
1 periodic fever, familial, autosomal dominant 12.4
2 thyroid dyshormonogenesis 1 11.7
3 neural tube defects 11.4
4 coronary artery dissection, spontaneous 11.4
5 nerve compression syndrome 11.4
6 gas gangrene 11.4
7 dehydrated hereditary stomatocytosis 1 with or without pseudohyperkalemia and/or perinatal edema 11.3
8 spondyloenchondrodysplasia with immune dysregulation 11.3
9 epidermoid brain cyst 11.3
10 duodenal atresia 11.1
11 hepatic fibrosis, severe due to schistosoma mansoni infection 11.1
12 dehydrated hereditary stomatocytosis 2 11.1
13 tonsillitis 11.1
14 fox-fordyce disease 11.1
15 miliaria 11.1
16 paraphimosis 11.1
17 priapism 11.1
18 catamenial pneumothorax 11.1
19 autoimmune disease 10.4
20 aneurysm 10.4
21 vasculitis 10.4
22 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.4
23 lung disease 10.3
24 hair whorl 10.3
25 systemic lupus erythematosus 10.3
26 west nile virus 10.3
27 malaria 10.2
28 helix syndrome 10.2
29 cystic fibrosis 10.2
30 hydrocephalus 10.2
31 lupus erythematosus 10.2
32 congenital hydrocephalus 10.2
33 pulmonary disease, chronic obstructive 10.2
34 amyloidosis 10.2
35 kala-azar 1 10.2
36 leishmaniasis 10.2
37 pulmonary embolism 10.2
38 acute respiratory distress syndrome 10.2
39 anca-associated vasculitis 10.2
40 pulmonary alveolar microlithiasis 10.2
41 patent foramen ovale 10.2
42 encephalitis 10.2
43 thrombophilia due to thrombin defect 10.2
44 rapidly involuting congenital hemangioma 10.2
45 thrombosis 10.2
46 pica disease 10.2
47 vaccinia 10.1
48 chikungunya 10.1
49 exanthem 10.1
50 kidney disease 10.1

Graphical network of the top 20 diseases related to Triiodothyronine Receptor Auxiliary Protein:



Diseases related to Triiodothyronine Receptor Auxiliary Protein

Symptoms & Phenotypes for Triiodothyronine Receptor Auxiliary Protein

Clinical features from OMIM:

190445

Drugs & Therapeutics for Triiodothyronine Receptor Auxiliary Protein

Drugs for Triiodothyronine Receptor Auxiliary Protein (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 297)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Certoparin Approved, Investigational Phase 4
2
Linagliptin Approved Phase 4 668270-12-0 10096344
3
Verteporfin Approved, Investigational Phase 4 129497-78-5
4
Ranibizumab Approved Phase 4 347396-82-1 459903
5
Sodium citrate Approved, Investigational Phase 4 68-04-2
6
Thrombin Approved, Investigational Phase 4
7
Vorapaxar Approved Phase 4 618385-01-6
8
Sucralfate Approved Phase 4 54182-58-0
9
Histamine Approved, Investigational Phase 4 51-45-6 774
10
Ranitidine Approved Phase 4 66357-35-5, 66357-59-3 3001055
11
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
12
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
13
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
14
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
15
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
16
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
17 Dipeptidyl-Peptidase IV Inhibitors Phase 4
18 Incretins Phase 4
19 Photosensitizing Agents Phase 4
20 Citrate Phase 4
21 Gastrointestinal Agents Phase 4
22 Antacids Phase 4
23 Histamine Antagonists Phase 4
24
Histamine Phosphate Phase 4 51-74-1 65513
25 Anti-Ulcer Agents Phase 4
26 Histamine H2 Antagonists Phase 4
27
Bismuth Phase 4 7440-69-9 16682734 105143
28 Ranitidine bismuth citrate Phase 4
29 Bismuth tripotassium dicitrate Phase 4
30 Vaccines Phase 4
31 Bone Density Conservation Agents Phase 4
32 Calcium, Dietary Phase 4
33 Pharmaceutical Solutions Phase 4
34 Hormones Phase 4
35 Micronutrients Phase 4
36 Trace Elements Phase 4
37 Vitamins Phase 4
38 Nutrients Phase 4
39 Calciferol Phase 4
40 Vitamin D2 Phase 4
41 Ergocalciferols Phase 4
42 Anesthetics Phase 4
43
Iodine Approved, Investigational Phase 3 7553-56-2 807
44
tannic acid Approved Phase 3 1401-55-4
45
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
46
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
47
Rilonacept Approved, Investigational Phase 3 501081-76-1 104924
48
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
49
Warfarin Approved Phase 2, Phase 3 81-81-2 6691 54678486
50 Grape Approved Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 295)
# Name Status NCT ID Phase Drugs
1 Randomized-Double Blind Trial to Assess the Incidence and Clinical Relevance of Heparin-Induced Thrombocytopenia (HIT) Antibodies in Trauma Patients Treated With Unfractionated or Low-Molecular Weight Heparin, the HIT-TRAP Trial Unknown status NCT00196417 Phase 4 Standard heparin (UFH) versus certoparin (LMWH)
2 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
3 An Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Injection of VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy Completed NCT01950741 Phase 4 aflibercept
4 AflibercepT for Subjects Who Are Incomplete Responders to mUltiple Intravitreal Injections of Ranibizumab, Anti-VegF (The TURF Study) Completed NCT01543568 Phase 4 aflibercept 2.0 mg
5 A Randomized, Double-masked, Sham-controlled Phase 3b/4 Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy as Indicated in Subjects With Polypoidal Choroidal Vasculopathy Completed NCT02120950 Phase 4 Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
6 An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients With Neovascular Age-Related Macular Degeneration Completed NCT01722045 Phase 4 Intravitreal Aflibercept Injection (IAI)
7 Open-label Phase-4 Study to Examine the Change of Vision-related Quality of Life in Subjects With Diabetic Macular Edema (DME) During Treatment With Intravitreal Injections of 2 mg Aflibercept According to EU Label for the First Year of Treatment Completed NCT02581995 Phase 4 Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
8 Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy Completed NCT02072408 Phase 4 aflibercept
9 Managing Neovascular Age-related Macular Degeneration (nAMD) Over 2 Years With a Treat and Extend (T&E) Regimen of 2 mg Intravitreal Aflibercept - a Randomized, Open-label, Active-controlled, Parallel-group Phase IV/IIIb Study (ARIES) Completed NCT02581891 Phase 4 Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321);Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)
10 A Randomized, Open-label Phase 4 Study Evaluating the Efficacy and Safety of Repeated Doses of Intravitreal Aflibercept With Variable Treatment Intervals in Japanese Subjects With Neovascular Age-related Macular Degeneration Completed NCT02305238 Phase 4 Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
11 NEWTON: A Single-center Open Label Study Evaluating Intravitreal Aflibercept Injection (IAI) for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions Completed NCT01870427 Phase 4 Aflibercept (2.0 mg)
12 Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD) Completed NCT01663103 Phase 4 Rilonacept;Placebo
13 Efficacy of Intravitreal Aflibercept Monotherapy for Submacular Hemorrhage Secondary to Neovascular Age-Related Macular Degeneration: A Prospective Clinical Trial Completed NCT03169660 Phase 4 Vascular endothelial growth factor trap-eye
14 Vorapaxar in the Human Endotoxemia Model A Randomized, Double‐Blind, Crossover Study Completed NCT02875028 Phase 4 Vorapaxar;Placebo
15 A Multi-center, Single-arm, Interventional Phase 4 Study to Evaluate a Treat and Extend Regimen of Intravitreal Aflibercept for Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion Completed NCT02800642 Phase 4 Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
16 Intravitreal Aflibercept (VEGF Trap-Eye) in Neovascular Age-related Macular Degeneration With Limited Response to Ranibizumab Completed NCT02309281 Phase 4 aflibercept 2mg
17 A Clinico-Bacteriological Study and Effect of Stress Ulcer Prophylaxis on Occurrence of Ventilator Associated Pneumonia: a Randomized Prospective Study Completed NCT00702871 Phase 4 Ranitidine;Sucralfate
18 Grass Pollen Subcutaneous Immunotherapy: a Double-blind, Placebo-controlled Study in Elderly Patients With an Allergy to Grass Pollen Completed NCT02440243 Phase 4 Purethal;Purethal -placebo
19 Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence: an Open-label Randomized Controlled Trial: TRAPIST - TRAP Intervention STudy Recruiting NCT02621645 Phase 4
20 Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study: A Randomized Controlled Trial of the Efficacy of HPV Vaccination in Preventing Transmission of HPV Infection in Heterosexual Couples Recruiting NCT01824537 Phase 4
21 Effect of Vitamin D3 Supplementation on Arterial and Bone Remodeling in Chronic Kidney Disease Patients Recruiting NCT02999204 Phase 4 Vitamin D3
22 Estimation of MMP-8 Levels in GCF and Serum and Its Correlation With Wound Healing and Clinical Outcomes After Coronally Advanced Flap and Subepithelial Connective Tissue Graft for Root Coverage in Recession Defects: A CLINICO-BIOCHEMICAL STUDY Suspended NCT02863744 Phase 4
23 Influence of Preoperative Hemodialysis or Intraoperative Modified Ultrafiltration on Postoperative Outcome for Patients With Severe Renal Dysfunction Undergoing Open Heart Surgery: Randomized, Controlled, Multicenter Clinical Trial Unknown status NCT00720967 Phase 3
24 An Open-label Phase III Study Evaluating the Safety and Tolerability of Repeated Doses of Intravitreal VEGF Trap-Eye in Japanese Subjects With Diabetic Macular Edema Completed NCT01512966 Phase 3
25 A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap Eye in Subjects With Diabetic Macular Edema Completed NCT01783886 Phase 3
26 A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap-Eye in Subjects With Diabetic Macular Edema Completed NCT01331681 Phase 3
27 A Randomized, Double-masked, Photodynamic Therapy-controlled Phase-3 Study of the Efficacy, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Chinese Subjects With Neovascular Age-Related Macular Degeneration Completed NCT01482910 Phase 3 Visudyne
28 A Randomized, Double-masked, Sham-controlled Phase 3 Study of the Efficacy, Safety and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) Completed NCT01012973 Phase 3
29 A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion Completed NCT00943072 Phase 3 Sham
30 A Phase-3, Multi-center, Randomized, Double-masked, Sham-controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Subjects With Choroidal Neovascularization Secondary to Pathologic Myopia Completed NCT01249664 Phase 3
31 A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]) in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion Completed NCT01521559 Phase 3 Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
32 A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients With Diabetic Macular Edema Completed NCT01363440 Phase 3 Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)
33 An Open-label, Long-term, Safety and Tolerability Extension Study of Intravitreal VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration Completed NCT00964795 Phase 3 Intravitreal Aflibercept Injection 2mg
34 A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-Related Macular Degeneration Completed NCT00509795 Phase 3
35 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study of the Effect of Intravenous Aflibercept Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites Completed NCT00327444 Phase 2, Phase 3 aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®);Placebo;aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
36 WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation (PROTECT AF) Completed NCT00129545 Phase 2, Phase 3 Warfarin
37 Three-month Outcome of Ziv-aflibercept for Diabetic Macular Edema Completed NCT02772497 Phase 2, Phase 3 Ziv aflibercept
38 A Randomized, Double Masked, Active Controlled, Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-related Macular Degeneration (AMD) Completed NCT00637377 Phase 3 Ranibizumab
39 Correction of Vitamin D Deficiency in Critically Ill Patients: a Randomized, Double-blind, Placebo-controlled Trial ("VITDAL@ICU") Completed NCT01130181 Phase 3 Cholecalciferol;Placebo
40 Randomized, Cross-Over, Double Blind, Placebo-Controlled Study of Grape Seed Extract in Treating Patients With Mild Hyperlipidemia Completed NCT00713167 Phase 2, Phase 3 Grape Seed Extract (Vitagrape);Placebo of Grape Seed Extract
41 A Multinational, Randomized, Double-Blind Study Comparing Aflibercept Versus Placebo in Patients Treated With Second-Line Docetaxel After Failure of One Platinum Based Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Completed NCT00532155 Phase 3 Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®);Placebo;Docetaxel (Taxotere®);Dexamethasone (pre- and post-medication for docetaxel)
42 Nitric Oxide Administration During Pediatric Cardiopulmonary Bypass Surgery to Prevent Platelet activation-a Single Center Pilot Study Completed NCT03455218 Phase 2, Phase 3 Nitric Oxide;Placebo
43 IL1T-AI-0505: A Multi-center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, & Efficacy of Rilonacept in Subjects With Cryopyrin-Associated Periodic Syndromes (CAPS) Using Parallel Group & Randomized Withdrawal Designs Completed NCT00288704 Phase 3 rilonacept 160 mg;Placebo;rilonacept 160 mg
44 Trial to Reduce Alloimmunization to Platelets (TRAP) Completed NCT00000589 Phase 3
45 A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks Versus Placebo in Patients With Metastatic Colorectal Cancer (MCRC) Treated With Irinotecan / 5-FU Combination (FOLFIRI) After Failure of an Oxaliplatin Based Regimen Completed NCT00561470 Phase 3 Placebo;Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®);FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin);FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
46 Sequential Preoperative Ipsilateral Hepatic Vein Embolization After Portal Vein Embolization to Induce Further Liver Regeneration in Patients With Hepatobiliary Malignancy Completed NCT00698880 Phase 2, Phase 3
47 Diagnosis of Ventilator- Associated Pneumonia in Children: A Comparative Study of Bronchoscopic and Non-Bronchoscopic Methods Completed NCT00495963 Phase 3
48 Pharmacokinetics of Low-dose Sofosbuvir in Dialysis-dependent Patients With Hepatitis C Virus Infection Recruiting NCT03883698 Phase 3 Sofosbuvir;Daclatasvir 60 mg
49 An Open-label, Randomized, Active-controlled, Parallel-group, Phase-3b Study of the Efficacy, Safety, and Tolerability of 2 mg Aflibercept Administered by Intravitreal Injections Using Two Different Treatment Regimens to Subjects With Neovascular Age-related Macular Degeneration (nAMD). Active, not recruiting NCT02540954 Phase 3 Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
50 Sustainability of Rehabilitation Gains in COPD Active, not recruiting NCT02241733 Phase 3

Search NIH Clinical Center for Triiodothyronine Receptor Auxiliary Protein

Genetic Tests for Triiodothyronine Receptor Auxiliary Protein

Anatomical Context for Triiodothyronine Receptor Auxiliary Protein

MalaCards organs/tissues related to Triiodothyronine Receptor Auxiliary Protein:

41
Bone, Neutrophil, Eye, Endothelial, Testes, Liver, Brain

Publications for Triiodothyronine Receptor Auxiliary Protein

Articles related to Triiodothyronine Receptor Auxiliary Protein:

(show top 50) (show all 30002)
# Title Authors PMID Year
1
3,5,3'-triiodothyronine receptor auxiliary protein (TRAP) enhances receptor binding by interactions within the thyroid hormone response element. 38 8
1708100 1991
2
Influence of Oxygen Partial Pressure on Radio Frequency Magnetron Sputtered Amorphous InZnSnO Thin Film Transistors. 38
31383163 2020
3
Improved segmented-scan spectral stitching for stable isotope resolved metabolomics (SIRM) by ultra-high-resolution Fourier transform mass spectrometry. 38
31409459 2019
4
Comprehensively qualitative and quantitative analysis of ginsenosides in Panax notoginseng leaves by online two-dimensional liquid chromatography coupled to hybrid linear ion trap Orbitrap mass spectrometry with deeply optimized dilution and modulation system. 38
31387717 2019
5
On the origin of thaw loss: Relationship between freezing rate and protein denaturation. 38
31279125 2019
6
Effect of pH on the reaction between naringenin and methylglyoxal: A kinetic study. 38
31272050 2019
7
Analysis of Electrical Characteristics of InAlGaN/GaN-Based High Electron Mobility Transistors with AlGaN Back Barriers. 38
31026900 2019
8
Effect of Interface Traps on the Device Performance of InGaAs-Based Gate-All-Around Tunneling Field-Effect Transistors. 38
31026904 2019
9
Si/Ge Hetero Tunnel Field-Effect Transistor with Junctionless Channel Based on Nanowire. 38
31027023 2019
10
Identification and quantification of new isomers of isopropyl-malic acid in wine by LC-IT and LC-Q-Orbitrap. 38
31126479 2019
11
The effects of myokines on osteoclasts and osteoblasts. 38
31395341 2019
12
Combustion synthesis of electrospun LaInO nanofiber for high-performance field-effect transistors. 38
31386631 2019
13
Determination of pesticide levels in wastewater from an agro-food industry: Target, suspect and transformation product analysis. 38
31154175 2019
14
Trace metal comparative analysis of sinking particles and sediments from a coastal environment of the Jiaozhou Bay, North China: Influence from sediment resuspension. 38
31154193 2019
15
Effects of Microwave Annealing on High-k Dielectric HfO₂ Thin Films. 38
31026942 2019
16
Emission reduction characteristics of a catalyzed continuously regenerating trap after-treatment system and its durability performance. 38
31284908 2019
17
Influence of Self-Heating Effect on Interface Trap Generation in Highly Flexible Single-Crystalline Si Nanomembrane Transistors. 38
31026981 2019
18
Gate Voltage Dependence of Low Frequency Noise in Tunneling Field Effect Transistors. 38
31026912 2019
19
Micro-Acoustic-Trap (µAT) for microparticle assembly in 3D. 38
31208614 2019
20
Ultrasonic-assisted fabrication and release kinetics of two model redox-responsive magnetic microcapsules for hydrophobic drug delivery. 38
31078396 2019
21
Analysis of Minority Carrier Lifetime Dependence on Dual Gate Feedback Field Effect Transistor. 38
31027026 2019
22
Effect of polyvinylpolypyrrolidone treatment on rosés wines during fermentation: Impact on color, polyphenols and thiol aromas. 38
31174786 2019
23
Relationship between dietary non-enzymatic antioxidant capacity and type 2 diabetes risk in the Japan Public Health Center-based Prospective Study. 38
31212252 2019
24
Deiminated proteins in extracellular vesicles and plasma of nurse shark (Ginglymostoma cirratum) - Novel insights into shark immunity. 38
31200072 2019
25
Hybrid channel induced forming-free performance in nanocrystalline-Si:H/a-SiNx:H resistive switching memory. 38
31137019 2019
26
The effect of risedronate on orthodontic tooth movement in ovariectomized rats. 38
31276939 2019
27
Capillary electrophoresis study on segment/segment system and its role in characterization of nanoparticles. 38
31176483 2019
28
Municipal wastewater effluent affects fish communities: A multi-year study involving two wastewater treatment plants. 38
31284215 2019
29
Mapping Unsaturation in Human Plasma Lipids by Data-Independent Ozone-Induced Dissociation. 38
31222675 2019
30
Animal learning may contribute to both problems and solutions for wildlife-train collisions. 38
31352891 2019
31
Oleanolic acid inhibits RANKL-induced osteoclastogenesis via ER alpha/miR-503/RANK signaling pathway in RAW264.7 cells. 38
31176167 2019
32
A pectin-gelatin gel containing oral rehydration solution and the release of sodium chloride under simulated gastric conditions. 38
31233797 2019
33
Nirogacestat suppresses RANKL-Induced osteoclast formation in vitro and attenuates LPS-Induced bone resorption in vivo. 38
31211955 2019
34
PSTPIP2 attenuates joint damage and suppresses inflammation in adjuvant-induced arthritis. 38
31325437 2019
35
Identification of neutral and acidic glycosphingolipids in the human dermal fibroblasts. 38
31251925 2019
36
Combined Use of a Fiberscope and Fuji Uniblocker for Removal of Retained Bronchial Tissue Glue After Repair of a Disrupted Left Main Bronchus. 38
30058475 2019
37
An estimate to the first approximation of microtubule rupture force. 38
31134309 2019
38
Insight into the redox status of inflammatory skin equivalents as determined by EPR spectroscopy. 38
31330126 2019
39
Association study of dietary non-enzymatic antioxidant capacity (NEAC) and colorectal cancer risk in the Spanish Multicase-Control Cancer (MCC-Spain) study. 38
29995245 2019
40
Population Pharmacokinetic Analysis of Bintrafusp Alfa in Different Cancer Types. 38
31278692 2019
41
Effect of temperature on the actomyosin-paramyosin structure from giant squid mantle (Dosidicus gigas). 38
31077364 2019
42
Study of Anopheles gambiae 3-hydroxykynurenine transaminase activity and inhibition by LC-MS/MS method. 38
31129535 2019
43
Impact force of a surge of water and sediments mixtures against slit check dams. 38
31132714 2019
44
Serial hyphenation of dried spot, reversed phase liquid chromatography, hydrophilic interaction liquid chromatography, and tandem mass spectrometry towards direct chemical profiling of herbal medicine-derived liquid matrices, an application in Cistanche sinensis. 38
31153135 2019
45
Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer. 38
31174237 2019
46
Studies on oral bioavailability and first-pass metabolism of withaferin A in rats using LC-MS/MS and Q-TRAP. 38
31062367 2019
47
Application of a needle trap device packed with XAD-2 polyaniline composite for sampling naphthalene and phenanthrene in air. 38
31176481 2019
48
UV-Vis Photodissociation Action Spectroscopy on Thermo LTQ-XL ETD and Bruker amaZon Ion Trap Mass Spectrometers: a Practical Guide. 38
31087269 2019
49
Extracellular DNA traps in inflammation, injury and healing. 38
31213698 2019
50
Development and performance evaluation of a novel dynamic headspace vacuum transfer "In Trap" extraction method for volatile compounds and comparison with headspace solid-phase microextraction and headspace in-tube extraction. 38
31178163 2019

Variations for Triiodothyronine Receptor Auxiliary Protein

Expression for Triiodothyronine Receptor Auxiliary Protein

Search GEO for disease gene expression data for Triiodothyronine Receptor Auxiliary Protein.

Pathways for Triiodothyronine Receptor Auxiliary Protein

GO Terms for Triiodothyronine Receptor Auxiliary Protein

Sources for Triiodothyronine Receptor Auxiliary Protein

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....